Lawmakers raising national safety issues and seeking to disconnect a serious Chinese firm from U.S. pharmaceutical interests have rattled the biotech business. The firm is deeply concerned in improvement and manufacturing of essential therapies for most cancers, cystic fibrosis, H.I.V. and other diseases. The company reported outcomes of scientific trials involving Zepbound, an obesity drug in the identical class as Novo Nordisk’s Wegovy. New regimens in development, including once-weekly drugs and semiannual photographs, could assist control the virus in hard-to-reach populations. After a drawn-out international controversy over the coronavirus, the W.H.O. has updated its classification of how pathogens unfold via…